Brief: Spyre Therapeutics Reports Positive 12-Week Phase 2 Data For SPY001 In Skyline Trial
13/04/2026 12:00
April 13 (Reuters) - Spyre Therapeutics Inc SYRE.O: SPYRE THERAPEUTICS: SPY001 MET PRIMARY ENDPOINT SHOWING STATISTICALLY SIGNIFICANT REDUCTION IN RHI SCORE OF 9.2 POINTS SPYRE THERAPEUTICS: ANNOUNCES POSITIVE 12-WEEK INDUCTION DATA FROM PART A OF PHASE 2 SKYLINE TRIAL OF SPY001 SPYRE THERAPEUTICS: SECONDARY ENDPOINTS INCLUDED CLINICAL REMISSION BY MODIFIED MAYO SCORE OF 40% & ENDOSCOPIC IMPROVEMENT OF 51% SPYRE THERAPEUTICS: THERE WERE SIX SUBJECTS WITH TREATMENT-EMERGENT ADVERSE EVENTS DURING INDUCTION TREATMENT PERIOD Further company coverage: SYRE.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Spyre Therapeutics
See all newsU.S. STOCKS ON THE MOVE-Becton Dickinson, Constellation Energy, Marvell
U.S. STOCKS ON THE MOVE-Constellation Energy, AMD
U.S. STOCKS ON THE MOVE-MYR Group, Spyre Therapeutics, AMD
Spyre Therapeutics slips on $350 mln share sale
Brief: Spyre Therapeutics Announces Pricing Of $350.0 Million Public Offering Of Common Stock